A Randomized Double-Blind Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and
bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin
in treating patients with urinary tract cancer that has spread to other places in the body.
Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet
known whether gemcitabine hydrochloride and cisplatin are more effective when given with or
without bevacizumab in treating patients with urinary tract cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.